Novo Nordisk, Wegovy
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) label. This update in the European Union (EU) reflects new data indicating the product’s ability,
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST]
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Regulatory Oversight News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
Fake Ozempic: How batch numbers help criminal groups spread dangerous drugs
Fake Ozempic adds to a glut of counterfeit pharmaceuticals that kill around a million people each year, according to the WHO.
Criminal gangs are spreading dangerous fake weight-loss drugs across the world
Fake Ozempic adds to a glut of counterfeit pharmaceuticals that kill around a million people each year, according to the WHO.
EU plans Sept 25 vote on raising tariffs on EVs from China, Bloomberg News reports
The European Union is aiming to hold a vote to introduce definitive tariffs on electric vehicles imported from China on Sept.
Why Roche Holdings Stock Withered on Wednesday
For the second trading session in less than a week, Roche Holding ( RHHBY 3.83%) stock really took it on the chin Wednesday.
healthday on MSN11d
Wegovy, Ozempic May Someday Be Given as Once-Monthly Injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...